PL2020996T3 - Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego - Google Patents

Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego

Info

Publication number
PL2020996T3
PL2020996T3 PL07794933T PL07794933T PL2020996T3 PL 2020996 T3 PL2020996 T3 PL 2020996T3 PL 07794933 T PL07794933 T PL 07794933T PL 07794933 T PL07794933 T PL 07794933T PL 2020996 T3 PL2020996 T3 PL 2020996T3
Authority
PL
Poland
Prior art keywords
hematological malignancies
compositions
treating hematological
compound
salt
Prior art date
Application number
PL07794933T
Other languages
English (en)
Inventor
Lee S Chong
William A Lee
Adrian S Ray
Hans C Reiser
Daniel B Tumas
William J Watkins
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PL2020996T3 publication Critical patent/PL2020996T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Processing Of Solid Wastes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07794933T 2006-05-16 2007-05-16 Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego PL2020996T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80098306P 2006-05-16 2006-05-16
US83180506P 2006-07-18 2006-07-18
PCT/US2007/011726 WO2007136650A2 (en) 2006-05-16 2007-05-16 Method and compositions for treating hematological malignancies
EP07794933A EP2020996B1 (en) 2006-05-16 2007-05-16 Method and compositions for treating hematological malignancies

Publications (1)

Publication Number Publication Date
PL2020996T3 true PL2020996T3 (pl) 2012-04-30

Family

ID=38578698

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07794933T PL2020996T3 (pl) 2006-05-16 2007-05-16 Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego

Country Status (19)

Country Link
US (3) US20090258840A1 (pl)
EP (1) EP2020996B1 (pl)
JP (2) JP5544165B2 (pl)
KR (1) KR101424832B1 (pl)
CN (1) CN101442994B (pl)
AT (1) ATE534377T1 (pl)
AU (1) AU2007254309B2 (pl)
BR (1) BRPI0711646C1 (pl)
CA (1) CA2652048C (pl)
CY (1) CY1112377T1 (pl)
DK (1) DK2020996T3 (pl)
EA (1) EA016995B1 (pl)
ES (1) ES2377467T3 (pl)
MX (1) MX2008014665A (pl)
NZ (1) NZ572368A (pl)
PL (1) PL2020996T3 (pl)
PT (1) PT2020996E (pl)
SI (1) SI2020996T1 (pl)
WO (1) WO2007136650A2 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
DK2020996T3 (da) * 2006-05-16 2012-02-27 Gilead Sciences Inc Fremgangsmåder og sammensætninger til behandling af hæmatologiske sygdomme
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20200028498A (ko) 2010-06-24 2020-03-16 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
HUE061596T2 (hu) 2011-07-15 2023-07-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
WO2019237957A1 (zh) * 2018-06-12 2019-12-19 四川科伦博泰生物医药股份有限公司 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途
CN112168829B (zh) * 2020-09-24 2022-02-15 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
OA12393A (en) 2000-07-21 2006-04-18 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.
DE60221642T3 (de) * 2001-02-12 2017-10-26 Wyeth LLC (n.d.Ges.d. Staates Delaware) O-desmethyl-venlafaxine succinat salz
MXPA04003192A (es) * 2001-11-29 2004-07-27 Pfizer Prod Inc Sales de acido succinico de 5, 7, 14-triazatetraciclo ?10.3.1.02,11.04,9? -hexadeca-2(11), 3, 5, 7, 9-pentaeno y composiciones farmacetucias de las mismas.
HRP20040530A2 (en) * 2001-12-12 2004-10-31 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
US7214668B2 (en) * 2002-05-13 2007-05-08 Metabasis Therapeutics, Inc. Phosphonic acid based prodrugs of PMEA and its analogues
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
JP5144930B2 (ja) * 2003-08-18 2013-02-13 ハー・ルンドベック・アクチエゼルスカベット トランス−１−（６−クロロ−３−フェニルインダン−１−イル）−３，３−ジメチルピペラジン
ES2389602T3 (es) * 2003-12-30 2012-10-29 Gilead Sciences, Inc. Fosfonatos de nucleósidos y análogos de los mismos para el tratamiento de infecciones por el VPH
AU2005209256B2 (en) 2004-01-21 2010-11-18 Gilead Sciences, Inc. Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
WO2007075452A2 (en) * 2005-12-16 2007-07-05 Wyeth Lyophilized compositions of a triazolopyrimidine compound
DK2020996T3 (da) * 2006-05-16 2012-02-27 Gilead Sciences Inc Fremgangsmåder og sammensætninger til behandling af hæmatologiske sygdomme

Also Published As

Publication number Publication date
BRPI0711646A2 (pt) 2011-11-29
AU2007254309B2 (en) 2012-05-03
JP2009537539A (ja) 2009-10-29
WO2007136650A3 (en) 2008-01-24
CN101442994B (zh) 2013-03-06
US8435969B2 (en) 2013-05-07
ES2377467T3 (es) 2012-03-27
US20080039427A1 (en) 2008-02-14
PT2020996E (pt) 2012-02-20
MX2008014665A (es) 2008-11-28
CN101442994A (zh) 2009-05-27
EA200802333A1 (ru) 2009-04-28
EP2020996A2 (en) 2009-02-11
ATE534377T1 (de) 2011-12-15
US20090258840A1 (en) 2009-10-15
JP5544165B2 (ja) 2014-07-09
NZ572368A (en) 2011-04-29
KR20090015122A (ko) 2009-02-11
EP2020996B1 (en) 2011-11-23
CA2652048C (en) 2012-12-11
SI2020996T1 (sl) 2012-03-30
BRPI0711646B1 (pt) 2020-12-01
EA016995B1 (ru) 2012-09-28
WO2007136650A2 (en) 2007-11-29
CY1112377T1 (el) 2015-12-09
JP2013100324A (ja) 2013-05-23
DK2020996T3 (da) 2012-02-27
BRPI0711646B8 (pt) 2021-04-06
KR101424832B1 (ko) 2014-08-06
AU2007254309A1 (en) 2007-11-29
HK1127913A1 (en) 2009-10-09
CA2652048A1 (en) 2007-11-29
US20110172192A1 (en) 2011-07-14
BRPI0711646C1 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
PL2020996T3 (pl) Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
SG179418A1 (en) Inhibitors of the hedgehog pathway
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
TN2009000034A1 (en) Smac peptidomimetics useful as iap inhibitors
TN2010000293A1 (en) Thiazole derivatives used as pi 3 kinase inhibitors
PH12013500913A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
ECSP109953A (es) Derivados de piridazinona
EA201391705A1 (ru) Триазолпиридиновые ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i
CL2012000913A1 (es) Uso de una combinacion farmaceutica de compuestos especificos derivados de 4-morfolintieno[3,2-d]pirimidina con 3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil)(3-hidroxi-3-((2s)piperidin-2-il)azetidin-1-il)metanona para tratar localmente un tumor solido avanzado o metastasico.
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
NO20065416L (no) Hemming av fremstillingen av biogene sulfider via kombinasjoner av biocide og metabolske inhibitorer
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
TW200745094A (en) ATM inhibitor
MX2011007165A (es) Derivados de piridazinona.
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
UA101018C2 (ru) Пирролопиримидинкарбоксамиды
BRPI0821114A2 (pt) Composto, uso de um composto e método para tratar qualquer mamífero afetado por câncer
MX2009003102A (es) INDOLILALQUILPIRIDIN-2-AMINAS PARA LA INHIBICION DE ß-SECRETASA.
MX2009009917A (es) Derivados de tetrahidroquinolina y su uso para el tratamiento de cancer.
MX2009009916A (es) Tetrahidroquinolinas sustituidas.